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SYNOPSIS 
Locoregional recurrence (LRR) rate after total thyroidectomy and prophylactic unilateral central 
neck dissection was 1% per year in the first 5 years and dropped to 0.2% per year in the next 5 
years. Most (78.6%) LRRs involved the lateral compartment. Post-ablation stimulated 
thyroglobulin independently predicted LRR risk. 
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ABSTRACT 
Background: 
Prophylactic central neck dissection (pCND) at the time of the total thyroidectomy (TT) remains 
controversial in clinically nodal-negative (cN0) papillary thyroid carcinoma. Our study aimed to 
examine the predictive factors and pattern of locoregional recurrence (LRR) after pCND in the 
context of the postoperative sTg level. 
Methods: 
Three-hundred and forty-one patients who underwent TT and unilateral pCND were analyzed. 
Patients with an identifiable lesion on ultrasonography or whole-body scan within 6 months of 
surgery were excluded. A LRR was defined as an identifiable lesion on USG which was later 
confirmed by cytology/histology. Pre-ablation stimulated Tg (sTg) level was taken 2 months 
after surgery while post-ablation sTg level was taken 8 months after surgery. Cox regression was 
used in the univariate and multivariate analyses to identify significant independent factors for 
LRR.  
Results: 
After a follow-up of 66.6 ± 38.6 months, 14 (4.1%) suffered from LRR. The duration to first 
LRR was 36.4 ± 21.7 months. The estimated 5- and 10-year LRR rates were 5.1% and 6.1%, 
respectively. Of these 14 LRR, 3 (21.4%) involved the central compartment alone, 9 (64.3%) 
involved the lateral compartment alone and 2 (14.3%) involved both central and lateral 
compartments. After adjusting for other clinicopathological factors, post-ablation sTg level 
4 
 
≥1ug/L (HR=265.109,95%CI=1.132 – 62075.644,p=0.045) was the only independent predictor 
of LRR.  
Conclusions: 
Annualized risk of LRR after pCND was around 1% in the first 5 years and 0.2% in the 
subsequent 5 years. Most (78.6%) LRRs involved the lateral compartment. Post-ablation sTg 
≥1ug/L significantly predicted risk of LRR. 
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma with an age-
adjusted incidence doubled over the last 20 years [1,2]. Despite its relatively good prognosis, 
locoregional recurrence (LRR) is common [3]. With recognition of the concept of step-wise 
progression of nodal metastasis from the central (level VI) to the lateral compartment (levels II-
V) and preoperative ultrasonography (USG) only identifies roughly half of the central nodal 
metastasis (CNM), routine prophylactic central neck dissection (pCND) at the time of the total 
thyroidectomy (TT) has been advocated [4-6]. However, this remains controversial in clinically 
nodal-negative (cN0) PTC [7]. Although pCND may reduce of LRR in the short-term, it is at the 
expense of higher morbidity and cost [8,9]. 
Despite the increasing number of studies assessing the value of pCND, few studies have focused 
on evaluating the predictive factors and pattern of short to medium term LRR after pCND. Given 
that pCND is increasingly being performed, a better understanding of these factors and pattern 
may not only help to assess risk of LRR but also tailor decisions regarding the need for adjuvant 
therapy (such as radioactive iodine (RAI) ablation, degree of thyrotrophin suppression) and 
frequency of surveillance after pCND. Although studies have identified clinicopathologic factors 
predictive of LRR and nodal recurrence after pCND [10-12], these factors were not evaluated in 
the context of the biochemical response after initial operation and RAI ablation. It has been 
recognized that the biochemical response to treatment (namely, post-surgical thyroglobulin (Tg) 
levels) is a significant predictor of recurrence in low-risk PTC [7,13-15]. In view of these 
findings, our study aimed to examine predictive factors and pattern of LRR in cN0 PTC after 
pCND in the context of the postoperative sTg level.
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PATIENTS AND METHODS 
Patients 
From July 2003 – June 2013, 351 consecutive patients with cN0 PTC underwent surgery at our 
institution. To exclude the possibility of residual disease due to inadequate preoperative 
assessment and/or surgical resection, those with identifiable locoregional disease on USG or 
post-RAI whole-body scan (WBS) within 6 months of surgery were excluded. Therefore 341 
(97.2%) patients were eligible for analysis. All post-surgical patients were followed up within 4 
weeks in a multi-disciplinary oncology clinic. A follow-up visit was conducted at 3-month 
intervals in the first 2 years, 6-month in the subsequent 3 years and annually thereafter. Clinical 
examination, neck USG and non-stimulated Tg level were done during the follow-up visit. 
Locoregional recurrence (LRR) was made by a combination of basal Tg trend, USG, CT/ MRI or 
FDG-PET scan and confirmed by fine needle aspiration cytology (FNAC). LRR was defined as 
an identifiable lesion on USG which was later confirmed on FNAC and/or histology. The side 
and location of LRR was recorded. To ensure complete follow-up data of all 341 patients, a 
careful manual search of all patients’ status in the territory-wide Clinical Management System 
(CMS) was performed. The CMS is a computerized database linking up all public hospitals 
within our region. 
Methods 
All relevant clinical, laboratory, radiologic, and perioperative data were collected prospectively 
and follow-up data were regularly updated in a computerized database. Details of surgical 
treatment, criteria for radioactive iodine (RAI) ablation and follow-up protocol had been 
described previously.[16,17]  Total thyroidectomy was the preferred procedure for PTC ≥1cm. A 
routine ipsilateral pCND was performed for all regardless of tumor extent. The pCND consisted 
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of the removal of all nodes and fibro-fatty tissue extending vertically from the hyoid bone to the 
thoracic inlet and laterally from the medial border of common carotid artery to the midline of the 
trachea. The ipsilateral recurrent laryngeal nerve was mobilized along its entire cervical course. 
An intraoperative nerve stimulator was used to confirm its functional integrity [18]. Parathyroid 
autotransplantation was readily performed. 
Serum calcium and phosphate levels were measured postoperatively. Calcium +/- vitamin D 
supplements were prescribed if symptomatic or calcium <1.70mmol/L. Those who discontinued 
supplements in the presence of normocalcemia within 6 months were considered temporary and 
those who needed for >6 months were considered permanent hypoparathyroidism. Perioperative 
direct laryngoscopy was performed to assess vocal cord function. Vocal cord palsy (VCP) lasting 
> 6 months was regarded permanent. 
All postoperative Tg levels were measured at the same laboratory using the same immunometric 
assay. The assay used was the Immulite 2000 (Diagnostic Products Corp. Roche, Los Angeles, 
CA). This was calibrated against the CRM- 457 standard. Normal reference range was <0.5 – 55 
ug/L and sensitivity was <0.2 ug/L).Stimulated Tg (sTg) was defined as a Tg level measured in 
the presence of TSH >30 ug/L either by thyroxine withdrawal or recombinant TSH injections. 
The pre-ablation sTg level was taken approximately 2 months after surgery while the post-
ablation level was taken approximately 8 months after surgery (6-7 months after RAI ablation). 
Tg autoantibodies were measured at the same time and those with elevated Tg autoantibodies 
were excluded from Tg analysis. The decision for RAI ablation was based on presence of ≥1 risk 
factors such as tumor size >1.5cm, CNM, extrathyroidal extension and microscopic positive 
margin. Three giga-Becquerels (GBq) or 80millicuries (mCi) I131 was given as a standard fixed 
ablative dose.  
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Statistical analysis 
Statistical analysis was performed by chi-square or Fisher’s Exact test to compare categorical 
variables, and Mann-Whitney U was used to compare continuous variables between groups. For 
correlation between two continuous variables, the Pearson correlation test was performed. 
Continuous variables were expressed as mean±SD. LRR rate was estimated using the Kaplan-
Meier method. Variables which were significant in the univariate analysis were entered into 
multivariate analysis. Cox regression analysis with a variable entrance criterion of 0.05 or less 
was conducted to identify independent factors. All statistical analyses were performed using 
SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA).
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RESULTS 
Our cohort was mostly females (81.5%) and ethnic Chinese (88.0%). The mean age at operation 
was 49.0 ± 14.6 years old. The mean (±SD) tumor size was 1.73 ± 1.12cm. The mean (±SD) total 
number of CLNs and positives CLNs retrieved after unilateral pCND were 7.2 ± 4.1 and 1.8 ± 
2.3, respectively. The incidence of CNM was 22.3%. In terms of surgical morbidity, 19 (5.6%) 
suffered from temporary VCP while 2 (0.6%) developed permanent VCP.  Four (1.2%) patients 
developed permanent hypoparathyroidism while 44 (12.9%) patients suffered from temporary 
hypoparathyroidism. After a mean follow-up of 66.6 ± 38.6 months, all patients were still alive. 
There were 14 patients with LRR. Of these 14 LRR, 3 involved the central compartment alone 
while 9 involved the lateral compartment alone and 2 involved both central and lateral 
compartments. There were no recurrences in the thyroid bed or tracheal wall. The mean duration 
to first LRR was 36.4 ± 21.7 months. The estimated 5- and 10-year LRR rates were 5.1% and 
6.1%, respectively. 
Table 1 shows a comparison of clinicopathological features between those with LRR (group I) 
and those without LRR (group II). Extrathyroidal extension, multifocality and lymphovascular 
invasion (LVI) and CNM were significantly more common in group I (p<0.05). However, among 
those with tumor multifocality, those with ≥3 tumor foci were not associated with a higher LRR 
rate than 2 foci (6/53 vs. 8/62, p=1.000). Central lymph node ratio (CLNR) was significantly 
higher in group I than II (72.9% vs. 24.2%, p=0.010). Both pre-ablation sTg and post-ablation 
sTg levels were significantly higher in group I than II (11.2 vs. 7.5ug/L,p<0.001 and 6.2 vs. 3.8 
ug/L,p<0.001). 
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Table 2 shows the univariate analysis of LRR using Cox-regression. Similar to the direct 
comparison between group I and II, tumor multifocality, LVI, CLNR, CNM, pre-ablation sTg 
and post-ablation sTg were significantly associated with rate of LRR. 
Table 3a shows the multivariate analysis of clinicopathological factors for LRR.  Both tumor 
multifocality (HR=6.783, 95%CI=1.440 – 31.957,p=0.015) and CNM (HR=6.713, 
95%CI=1.613 – 27.936,p=0.009) were independent prognostic predictors for higher LRR.  
Table 3b shows the multivariate analysis of all factors for LRR. Since pre-ablation sTg and post-
ablation were inter-related, both were entered in a separate Cox-regression for LRR and post-
ablation sTg was the only significant factor of the two (data not shown). Therefore, only five 
significant factors (not including pre-ablation sTg) were entered into the multivariate analysis. 
After adjusting for the other four clinicopathological factors, post-ablation sTg level (HR=1.017; 
95%CI=1.001 – 1.054,p=0.041) was the only independent predictor. When post-ablation sTg 
was entered as a categorical variable (<1, ≥1ug/L), HR (95%CI) became 265.109 (1.132 – 
62075.644), p=0.045. After excluding those with Tg autoantibodies, if patients were categorized 
into 3 groups based on post-ablation sTg level (<1ug/L (n=216), ≥1ug/L but <10.0ug/L (n=67) 
and ≥10.0ug/L (n=31)), the 10-year LRR rates were 0.0%, 23.3% and 33.7%, respectively 
(p<0.001). Figure 1 shows the cumulative LRR curves between these three groups. 
Table 4 shows a summary of the 14 patients who developed LRR after pCND. None of these 
patients had detectable Tg autoantibodies. The lowest post-ablation sTg to develop LRR was 
1.1ug/L and that patient developed LRR 31.7 months after pCND. Nine of the 14 patients with 
LRR had post-ablation sTg ≥1ug/L but <10.0ug/L and the other 5 patients had post-ablation sTg 
≥ 10.0ug/L. There was no significant correlation between CLNR and time to LRR (ρ=0.250, 
p=0.388) or between post-ablation sTg and time to LRR (ρ=0.041, p=0.888). 
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DISCUSSION 
This was one of the first studies aimed at evaluating the predictive factors and pattern of cN0 
PTC after pCND in the context of postoperative sTg levels. Unlike previous studies, our analysis 
only analyzed patients with no identifiable lesion on USG and WBS within 6 months of initial 
operation. Our data showed that the chance of LRR was very low. The 5- and 10-year LRR rates 
were 5.1% and 6.1%, respectively. These data implied that the estimated LRR rate for the first 5 
years was approximately 1% per year and dropped to an even lower level (approximately 0.2% 
per year) for the subsequent 5 years. Barczynski et al. reported similar results in a large cohort 
and found the 5- and 10-year LRR rates after bilateral pCND to be 4.3% and 5.5%, respectively 
[18]. Kruijff et al. also recently reported similar rates with 5- and 10-year rates of 5% and 8%, 
respectively, although their cohort did not comprise entirely cN0 PTC patients [19]. Hartl et al. 
reported an even lower LRR rate when their 317 patients who underwent both bilateral pCND 
and prophylactic ipsilateral lateral neck dissection were analyzed. They reported that only 2 
(0.6%) patients developed LRR after a median follow-up of 4 years [20]. However, given the 
likelihood of higher morbidity in a disease with an already excellent prognosis, the cost benefit 
ratio of routine lateral neck dissection would be questionable [21]. 
In terms of the pattern of LRR, our data showed that the majority of LRR (11/14 or 78.6%) were 
mostly located in the lateral compartment. Of the 14 LRRs, 9 (64.3%) were solely confined to 
the lateral compartment while 3 (21.4%) occurred solely in the central compartment. Kruijff et al. 
reported that the rate of structural LRR in the lateral compartment almost doubled that of the 
central compartment after a more liberal use of unilateral pCND at the time of  TT (67% vs. 32%, 
p<0.01) [19]. Barczynski et al. reported a higher difference in LRR rate between lateral and 
central compartments after bilateral pCND (93.8% vs. 6.3%) [19]. In terms of which was the 
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most frequent involved side (relative to that of the primary tumor), the ipsilateral side was 
significantly more likely as the first site of LRR than contralateral side (72.7% vs. 9.1%). This 
finding agrees with previous studies [10-12,18-20] and could be explained by the step-wise 
progression of nodal metastasis originating from the ipsilateral central to ipsilateral lateral 
compartment [4]. In fact, since all 14 patients with LRR had at least one CLN containing 
metastasis (pN1a) at initial operation, we postulate that perhaps some of these patients with LRR 
might have had small volume of disease in the lateral compartment(s) which was present at 
initial operation but remained undetectable by USG and WBS in 6 months after surgery. This 
postulation is supported by the fact that both the pre-ablation sTg and post-ablation sTg levels 
were significantly higher in those with than without LRR and therefore, this implied that there 
was a small volume of residual disease which was detectable biochemically but not 
radiologically. 
In terms of which factors might help in predicting LRR, our data found post-ablation sTg level to 
be the most significant predictor for LRR. Although, previous studies have identified several 
clinicopathologic factors such as tumor size, CNM and CLNR to be associated with higher LRR, 
they did not analyze them in the context of post-surgical sTg levels. Several studies including the 
2009 revised American Thyroid Association guidelines have emphasized the importance of the 
biochemical response to treatment and found that incorporating it into the traditional risk 
stratification (or the so-called “dynamic risk assessment”) could provide a more accurate 
assessment on recurrence risk [7,23,24]. Based on the classification of response to initial therapy 
6-24 months after RAI as described by Tuttle et al., 9 of our 14 LRRs would have been classified 
as “acceptable response” while the other 5 as “incomplete response”. According to the same 
study, half of the latter group would have harbored structurally identifiable disease [23].  
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The implications are firstly, the biochemical response after treatment remained the most 
important predictor of LRR after TT and unilateral pCND. Our multivariate analysis (Table 3b) 
confirmed that post-ablation sTg was most significant among other clinicopathologic factors 
described in this and other studies [19,20]. Nevertheless, since post-ablation sTg is not available 
before RAI, multifocality and CNM remained important in the decision for RAI (Table 3a). 
Secondly, those with post-ablation sTg<1 ug/L had little to no LRR risk whereas those with post-
ablation sTg ≥1 ug/L had significantly higher LRR risk. Perhaps, this higher risk group should 
undergo longer TSH suppression and more intense surveillance studies, although the real benefits 
of these measures on recurrence or mortality remain unclear. On the other hand, those with lower 
risk might require less suppression and surveillance. Thirdly, since 11 (78.6%) LRR had some 
lateral compartment involvement, perhaps those patients at-risk of LRR should have more 
careful follow-up studies on their lateral compartments especially in the first 5 years of surgery. 
Despite these findings, our data should be interpreted cautiously as this was a moderate-sized 
retrospective study with relatively short follow-up and few LRR. Furthermore, since all pCND 
were unilateral, contralateral CNM could not be completely ruled out. Nevertheless, our data 
only showed a low incidence of LRR (3/14) occurring in the contralateral side. Given the higher 
morbidity in bilateral pCND, we still believe unilateral pCND might be more preferable. Another 
shortcoming was that the few patients with post-ablation sTg ≥ 1ug/L might have overly 
exaggerated the percentages of LRR.    
Conclusion 
The incidence of LRR after seemingly curative TT with pCND was around 1% in the first 5 
years and 0.2% in the subsequent 5 years. Of these LRRs, the majority (78.6%) involved the 
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lateral compartment while the other 21.4% involved the central compartment only. The post-
ablation sTg was the most significant predictor of LRR with a tendency for higher rate of LRR 
with post-ablation sTg levels ≥1.0ug/L.
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Table 1. A comparison of clinicopathological characteristics between those with locoregional 
recurrence (Group I) and those without (Group II) 
Variables Group I (n=14) Group II (n=327) p-value 
Age (years) 48.9 ± 15.7 49.1 ± 14.5 0.797 
Sex (male : female) 2 : 12 61 : 266 0.889 
Presented as a palpable swelling 11 (78.6) 235 (71.9) 0.358 
Preoperative serum TSH (mIU/L) 1.0 ± 0.3 1.4 ± 1.2 0.408 
Tumor size (cm) 
 - >1.5cm 
1.9 ± 0.9 
7 (50.0) 
1.7 ± 1.1 
128 (39.1) 
0.517 
0.418 
Extrathyroidal extension 6 (42.9) 83 (25.4) 0.041 
Multifocality 9 (64.3) 96 (29.4) 0.008 
Lymphovascular invasion 5 (35.7) 39 (11.9) 0.009 
Coexisting thyroiditis 2 (14.3) 52 (15.9) 0.651 
Tumor bilaterality 2 (14.3) 64 (19.6) 0.557 
Number of CLNs retrieved 5.2 ± 1.5 7.3 ± 4.2 0.683 
Number of positive CLNs retrieved 3.6 ± 1.6 1.7 ± 2.3 0.096 
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CLNR 72.9 ± 27.6 24.2 ± 27.8 0.010 
CNM (pN1a) 14 (100.0) 62 (19.0) <0.001 
Stage by TNM 
- Stage I / II 
- Stage III / IV 
 
10 (71.4) 
4 (28.6) 
 
214 (65.4) 
113 (34.6) 
0.105 
MACIS score 5.2 ± 5.0 4.9 ± 4.6 0.531 
RAI ablation 14 (100.0) 239 (73.1) 0.110 
Pre-ablation sTg (ug/L)# 11.2 ± 11.4 7.5 ± 13.6 <0.001 
Post-ablation sTg (ug/L)# 6.2 ± 10.9 3.8 ± 5.8 <0.001 
Abbreviations: TSH = Thyroid stimulating hormone; CLNR = central lymph node ratio; CNM = 
central nodal metastasis; TNM = 7th edition Tumor, Node and Metastasis staging system; MACIS 
= Metastases, Age, Completeness of surgery, Invasion and Size; RAI = radioiodine; sTg = 
stimulated thyroglobulin 
#excluding those with Tg autoantibodies 
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Table 2. Univariate analysis of factors associated with locoregional recurrence after unilateral 
prophylactic central neck dissection 
 Univariate analysis 
Variables Hazard ratio 95% CI p-value 
Age 1.003 0.968 – 1.039 0.883 
Female sex 0.791 0.176 – 3.546 0.760 
Preoperative TSH level 1.821 0.517 – 6.452 0.351 
Primary tumor size 1.021 0.623 – 1.675 0.934 
Extrathyroidal extension 2.869 0.875 – 9.410 0.082 
Tumor multifocality 10.422 2.332 – 46.572 0.002 
Lymphovascular invasion 1.587 1.000 – 2.521 0.049 
Coexisting thyroiditis 1.242 0.258 – 5.984 0.787 
Tumor bilaterality 1.266 0.649 – 2.468 0.489 
No. of CLNs retrieved 0.887 0.724 – 1.087 0.248 
No. of positive CLNs retrieved 1.141 0.885 – 1.471 0.309 
CLNR 1.029 1.003 – 1.056 0.029 
CNM (pN1a) 8.738 2.303 – 33.158 0.001 
MACIS score 1.129 0.766 – 1.665 0.540 
Radioiodine ablation 2.977 0.194 – 45.786 0.434 
Pre-ablation sTg# 1.006 1.004 – 1.008 <0.001 
Post-ablation sTg# 1.016 1.010 – 1.022 <0.001 
Abbreviations: TSH = thyroid stimulating hormone; CLN = central lymph node; CNM = central 
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nodal metastases; CLNR = central lymph node ratio; CI = confidence interval 
#excluding those with Tg autoantibodies 
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Table 3a. Multivariate analysis of clinicopathological factors only (i.e. factors available before 
radioiodine ablation) for locoregional recurrence after unilateral prophylactic central neck 
dissection 
Covariates Hazard ratio 95% confidence interval p-value 
Tumor multifocality 6.783 1.440 – 31.957 0.015 
Lymphovascular invasion 2.288 0.635 – 8.264 0.206 
CLNR 1.022 0.991 – 1.053 0.168 
CNM (pN1a) 6713 1.613 – 27.936 0.009 
 
Table 3b. Multivariate analysis of all factors associated with locoregional recurrence after 
unilateral prophylactic central neck dissection 
Covariates Hazard ratio 95% confidence interval p-value 
Tumor multifocality 3.062 0.192 – 48.938 0.429 
Lymphovascular invasion 2.341 0.332 – 16.495 0.393 
CLNR 1.011 0.972 – 1.052 0.584 
CNM (pN1a) 1.973 0.875 – 2.15 0.966 
Post-ablation sTg* 1.027 1.001 – 1.054 0.041 
Abbreviations: CLNR = central lymph node ratio; CNM = central nodal metastases; sTg = 
stimulated thyroglobulin 
*if entered as a categorical variable with a cut-off of ≥1ug/L, the HR (95%CI) became 265.109 
(1.132 – 62075.644), p=0.045.
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Table 4. A summary of the 14 patients with locoregional recurrence (LRR) after unilateral central neck dissection 
 Age  / 
Sex 
ETE Multifocality 
/ no. of foci 
LVI CLNR CNM Post-ablation 
sTg (ug/L)# 
Time to LRR 
(months) 
Site of LRR (neck 
compartment) 
Patient 1 62/F + + / 2 + 7/9 + 12.0 97.2 Contralateral central  
Patient 2 30/F - -  + 1/8 + 17.0 28.9 Ipsilateral lateral 
Patient 3 20/M + + / 2 - 3/3 + 8.7 50.0 Ipsilateral lateral 
Patient 4 46/F + + / 2 + 3/5 + 45.1 40.6 Bilateral lateral 
Patient 5 44/F - + / 2 - 4/5 + 3.9 24.4 Contralateral lateral 
Patient 6 18/F - + / 4 - 5/5 + 2.5 55.3 Ipsilateral lateral 
Patient 7 54/F - + / 6 - 1/5 + 9.7 18.7 Bilateral central 
Patient 8 40/M + + / 11 - 5/5 + 1.1 31.7 Ipsilateral central & lateral 
Patient 9 51/F - - - 4/5 + 22.5 29.1 Ipsilateral lateral 
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Patient 10 66/F + + / 2 + 3/4 + 6.7 40.1 Contralateral central & lateral 
Patient 11 54/F - - - 3/5 + 13.4 14.9 Ipsilateral central 
Patient 12 77/F - - - 5/5 + 3.4 13.6 Ipsilateral lateral 
Patient 13 56/F - - - 4/5 + 3.7 44.7 Ipsilateral lateral 
Patient 14 57/F + + / 2 + 3/4 + 7.4 21.1 Ipsilateral lateral 
Abbreviations: + = present ; - = absent ; ETE = extrathyroidal extension ; LVI = lymphovascular invasion ; CLNR = central lymph 
node ratio; CNM = central nodal metastasis   
#none had Tg autoantobodies
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LEGENDS 
Figure 1.  The cumulative locoregional recurrence curve of the three groups with post-ablation 
stimulated thyroglobulin level (<1ug/L (n=216), ≥1ug/L but <10.0ug/L (n=67) and ≥10.0ug/L 
(n=31)) after excluding those with Tg autoantibodies. 
